Restarting Wellbutrin XL 300 mg and Initiating Atomoxetine 40 mg: Dosing and Monitoring
Since this patient is already tolerating Wellbutrin XL 300 mg once daily without side effects, restart it immediately at the full 300 mg dose in the morning; simultaneously initiate atomoxetine at 40 mg once daily in the morning, and schedule close follow-up at 2 weeks to monitor for tolerability, suicidality, cardiovascular effects, and treatment response.
Medication Regimen
Wellbutrin XL (Bupropion) Restart
- Dose: Resume at 300 mg once daily in the morning 1
- Rationale: The patient was previously tolerating this dose without side effects, so no titration is needed. The FDA label supports direct initiation at 300 mg for patients who have previously tolerated this dose 1
- Administration: Take in the morning, with or without food; swallow whole (do not crush, divide, or chew) to minimize seizure risk 1
Atomoxetine Initiation
- Starting dose: 40 mg once daily in the morning 2
- Titration plan: This 40 mg dose is appropriate as a starting dose for adults. Standard titration would increase to 60 mg after 7-14 days, then to 80 mg if needed, with a maximum of 100 mg/day or 1.4 mg/kg/day (whichever is lower) 2
- Administration: Take in the morning alongside Wellbutrin XL as the patient planned 3
Important caveat: Starting atomoxetine at 40 mg represents a moderate initial dose. While some guidelines suggest starting at lower doses (e.g., 25 mg) to minimize early adverse events 4, the 40 mg starting dose is within FDA-approved parameters and was the dose chosen by the provider in this case 2.
Critical Drug Interaction Consideration
There is a clinically significant pharmacokinetic interaction between bupropion and atomoxetine 5. Bupropion is a CYP2D6 inhibitor, and atomoxetine is primarily metabolized via CYP2D6 2. Research demonstrates that bupropion co-administration increases atomoxetine systemic exposure (AUC) by approximately 5-fold and decreases its active metabolite by 1.5-fold 5.
Practical Implications:
- The patient may experience higher atomoxetine plasma levels than expected for the 40 mg dose
- This increases the risk of atomoxetine-related adverse effects (nausea, vomiting, decreased appetite, somnolence, fatigue) 2
- Approximately 7% of the population are poor CYP2D6 metabolizers who naturally have higher atomoxetine levels; bupropion essentially creates this scenario pharmacologically in all patients 2
- Monitor closely for tolerability—if side effects emerge, consider reducing atomoxetine dose rather than escalating
Monitoring Protocol
Two-Week Follow-Up (Critical Window)
The planned 2-week follow-up is appropriate and evidence-based 2. At this visit, systematically assess:
1. Suicidality Screening (Highest Priority)
- Atomoxetine carries a black box warning for increased suicidal ideation in children and adolescents 2
- While adult data did not show this risk, close monitoring is still recommended during the first few months and at dose changes 2
- Explicitly ask about suicidal thoughts, clinical worsening, and unusual behavioral changes
- The patient denied suicidal ideation at baseline—document this and reassess
2. Cardiovascular Monitoring
- Measure heart rate and blood pressure 2
- Both medications can affect cardiovascular parameters
- Atomoxetine warnings exist for preexisting cardiovascular disease and significant cardiac abnormalities 2
3. Adverse Effects Assessment Ask specifically about:
- Atomoxetine-related: Nausea, vomiting, decreased appetite, somnolence, fatigue, abdominal pain 2
- Bupropion-related: Insomnia, agitation, motor restlessness, dry mouth 6, 1
- Interaction-amplified effects: Given the 5-fold increase in atomoxetine exposure, GI and sedation side effects may be more prominent 5
4. Psychiatric Symptom Monitoring
- Screen for emergent psychotic or manic symptoms (both medications carry warnings) 2, 1
- Assess for aggressive behavior or hostility 2
- Monitor for anxiety worsening or activation
5. ADHD Symptom Response
- While full response may take 4-8 weeks, early improvements may be evident 3
- Use standardized rating scales if available (e.g., Conners' Adult ADHD Rating Scale)
Ongoing Monitoring Schedule
Weeks 2-8:
- Contact every 2-4 weeks during titration phase if dose adjustments are made
- Monthly visits once stable 7
Long-term:
- Continue monitoring suicidality, cardiovascular parameters, and treatment response
- Atomoxetine typically requires 4-8 weeks for full therapeutic effect 3
- Bupropion's full antidepressant effect may take 4 weeks or longer 1
Titration Considerations
If the patient tolerates the initial regimen at 2 weeks:
- Atomoxetine: Can increase to 60 mg daily after 7-14 days, then to 80 mg if needed for optimal ADHD control 2, 3
- However, given the drug interaction increasing atomoxetine levels 5-fold 5, consider whether dose escalation is truly necessary or if the 40 mg dose may be therapeutically sufficient due to elevated plasma concentrations
- Wellbutrin XL: Maintain at 300 mg unless inadequate response after several weeks, at which point can increase to maximum 450 mg once daily 1
Common Pitfalls to Avoid
Underestimating the bupropion-atomoxetine interaction: This is not a minor interaction—the 5-fold increase in atomoxetine exposure is substantial 5
Aggressive atomoxetine titration: Given the interaction, slower titration or remaining at lower doses may be prudent
Missing suicidality screening: This is a black box warning for atomoxetine and must be systematically assessed 2
Inadequate cardiovascular monitoring: Both medications affect cardiovascular parameters; baseline and ongoing BP/HR monitoring is essential 2
Crushing or splitting Wellbutrin XL: This increases seizure risk—tablets must be swallowed whole 1
Evening dosing: Both medications should be taken in the morning to minimize insomnia risk 6, 1
Safety Considerations
Seizure risk: Bupropion lowers seizure threshold in a dose-dependent manner. The 300 mg dose is within safe limits, but avoid doses above 450 mg/day and ensure tablets are not crushed 1
Bipolar screening: Both medications carry warnings about precipitating manic episodes; ensure bipolar disorder has been ruled out 2, 1
Substance use: Document any alcohol or substance use, as these may interact with treatment or affect seizure threshold 1